Sanofi Features P-IIb (STREAM-AD) Study Data of Amlitelimab for the Treatment of Atopic Dermatitis at AAD’24
Shots:
- The 2 parts P-IIb (STREAM-AD) study assesses amlitelimab (250mg with 500mg loading dose, 250mg, 125mg, 62.5mg, Q4W) for treating moderate-to-severe atopic dermatitis patients (n=390) with inadequate control using topical therapies or where such therapies were inadvisable
- The data showed that the responders to amlitelimab in 2nd part of the study who attained EASI-75 or IGA 0/1 during 24wk. period (part 1) were re-randomized for 28wks. to evaluate the maintenance of clinical response (part 2). Patients continuing amlitelimab & those with withdrawn treatment maintained high responder rates in all dosing arms
- The pooled dose-arms analysis revealed IGA 0/1 response maintained in 71.9% vs 57% & EASI-75 response was maintained in 69% vs 61.6% with continued vs withdrawn treatment
Ref: Globenewswire | Image: Sanofi
Related News:- Sanofi Reports P-IIb Study (STREAM-AD) Results of Amlitelimab for the Treatment of Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
